- Biotech has a new startup model: Small team, big check and Chinese assetsA new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large chec…Endpoints · 2mo ago↗ source
- Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialA Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised…Endpoints · 2mo ago↗ source
- UCB bets $2B on Candid's T cell engager ambitionsKen Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UC…